SARS-CoV-2 specific antibody responses in COVID-19 patients

NISREEN M.A. OKBA; Marcel A Muller; Wentao Li; Chunyan Wang; Corine H. GeurtsvanKessel; Victor M. Corman; Mart M. Lamers; Reina S. Sikkema; Erwin de Bruin; Felicity D. Chandler; Yazdan Yazdanpanah; Quentin Le Hingrat; Diane Descamps; Nadhira Houhou-Fidouh; Chantal B. E. M. Reusken; Berend-Jan Bosch; Christian Drosten; Marion P.G. Koopmans; Bart L. Haagmans

The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.18.20038059 doi: medRxiv preprint Overall, the assays developed and validated in this study could be instrumental for patient contact tracing, serosurveillance studies, as well as vaccine evaluation studies. However, since various studies will be carried out in different labs, it is crucial to calibrate and standardize assays developed by different labs using well defined standard references as a part of diagnostic assay validation. This is not only needed to reduce interassay variability, but to also harmonize the results obtained from different labs using various assays (14) . This is crucial for better comparison and interpertaion of results from different studies as well as evaluation of vaccine trials, allowing for uniform assessment of immunogenicity, efficacy and better understanding of correlates of immune protection (15) . Thus, setting up reference panels is a vital element in our preparedness approaches to emerging viruses. All rights reserved. No reuse allowed without permission.